Evidence map›Paper›PMID 34902069›Full record

ReviewCurrent diabetes reports2021

Patient-Centered Diabetes Care of Cancer Patients.

Anupam Kotwal, Yee-Ming M Cheung, Grace Cromwell, Andjela Drincic, Houry Leblebjian, Zoe Quandt, Robert J Rushakoff, Marie E McDonnell

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. The impact of hyperglycaemia and/or type 2 diabetes on women with breast cancer undergoing or post-cytotoxic chemotherapy: a systematic literature review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Guideline
  3. Review
  4. Article
  5. Evaluation of a Pharmacist-Led Diabetes Management and Education Clinic on Glycemic Outcomes in Patients With Cancer.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  6. Article
  7. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.The Journal of clinical endocrinology and metabolism · 2023
    Article
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Anupam KotwalDivision of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA.
Yee-Ming M CheungDepartment of Endocrinology, Austin Health, Heidelberg, Victoria, Australia.
Grace CromwellDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA, 02115, USA.
Andjela DrincicDivision of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, NE, USA.
Houry LeblebjianDepartment of Pharmacy, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Zoe QuandtDivision of Endocrinology and Metabolism, University of California, San Francisco, CA, USA.
Robert J RushakoffDivision of Endocrinology and Metabolism, University of California, San Francisco, CA, USA.
Marie E McDonnellDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, 221 Longwood Avenue, Boston, MA, 02115, USA. mmcdonnell@bwh.harvard.edu.
Brigham and Women's Hospital · USUniversity of California, San Francisco · USUniversity of Nebraska Medical Center · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThere is a bidirectional relationship between cancer and diabetes, with one condition influencing the prognosis of the other. Multiple cancer therapies cause diabetes including well-established medications such as glucocorticoids and novel cancer therapies such as immune checkpoint inhibitors (CPIs) and phosphoinositide 3-kinase (PI3K) inhibitors. RECENT

findingsThe nature and severity of diabetes caused by each therapy differ, with some predominantly mediated by insulin resistance, such as PI3K inhibitors and glucocorticoids, while others by insulin deficiency, such as CPIs. Studies have demonstrated diabetes from CPIs to be more rapidly progressing than conventional type 1 diabetes. There remains a scarcity of published guidance for the screening, diagnosis, and management of hyperglycemia and diabetes from these therapies. The need for such guidance is critical because diabetes management in the cancer patient is complex, individualized, and requires inter-disciplinary care. In the present narrative review, we synthesize and summarize the most relevant literature pertaining to diabetes and hyperglycemia in the setting of these cancer therapies and provide an updated patient-centered framework for their evaluation and management.

Indexed as

Diabetes Mellitus, Type 1HyperglycemiaNeoplasmsGlucocorticoidsHumansImmune Checkpoint InhibitorsPatient-Centered CarePhosphoinositide-3 Kinase InhibitorsGlucocorticoidsImmune Checkpoint InhibitorsPhosphoinositide-3 Kinase InhibitorsDiabetes mellitusGlucocorticoidHyperglycemiaImmune checkpoint inhibitorPI3 kinase inhibitor

Identifiers

PMID34902069
OpenAlexW4200456193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.